Navigation Links
ABT is the Only Source for Kelo-cote(R) Advanced Formula Scar Gel
Date:6/25/2008

CLEARWATER, Fla., June 25 /PRNewswire/ -- Kelo-cote(R) advanced formula scar gel is a unique patented silicone formula using cross-link technology and has become the gold standard for scar treatment and abnormal scar prevention. The patented silicone formula in Kelo-cote(R) advanced formula scar gel is ONLY available from Advanced Bio-Technologies, Inc.(ABT).

Kelo-cote(R) is no longer available under the Dermatix label. Doctors and customers should not be misled by competitors' claims they offer the same product. Specifically, Valeant Pharmaceutical's claim that Dermatix and Dermatix Ultra contain the same formula or an improvement of Kelo-cote(R) advanced formula scar gel is FALSE. Dermatix and Dermatix Ultra are not manufactured by ABT and neither contains the Kelo-cote(R) formula.

Prior to July 2007, Kelo-cote(R) was available under the Dermatix label, but Valeant's license to market Kelo-cote(R) was terminated. Doctors should be aware that clinical data published under the brand name Dermatix prior to July 2007 was conducted using the current Kelo-cote(R) formula, but Kelo-cote(R) is no longer available under the Dermatix label.

To ABT's knowledge and belief, neither Dermatix nor Dermatix Ultra have clinical evidence supporting its efficacy. Kelo-cote(R) advanced formula scar gel has the ONLY clinically proven patented self-drying silicone formulation that creates a flexible, breathable silicone gel sheet. This is the reason Kelo-cote(R) advanced formula scar gel from ABT is the gold standard for scar treatment and prevention.

Kelo-cote(R) is manufactured by Advanced Bio-Technologies, Inc. headquartered in Clearwater, FL.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Lisa Massaad https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=67863


'/>"/>
SOURCE Advanced Bio-Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Decision Resources, Inc. Acquires Manhattan Research
2. Energetiqs Laser-Driven Light Source Technology Enables Continuous Spectrum Light Sources, from Visible to Deep Ultraviolet
3. New discoveries, new labs highlight international Canadian Light Source meeting
4. Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
5. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
6. Engineers demonstrate first room-temperature semiconductor source of coherent Terahertz radiation
7. Eklin Announces Acquisition of Ultrasource, Inc.
8. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
9. Global Blood Resources On-Line Calculator Reveals Wasted Blood Costs by Blood Salvage Machines During Heart Surgery to be in the Billions
10. /C O R R E C T I O N from Source -- Resverlogix Corp./
11. ETEX Announces Supply Agreement with AlloSource
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, ... data on its oral peptide drug candidates, PTG-100 ... of the European Crohn,s and Colitis Organization (ECCO).  ... Barcelona, Spain from February 15 ... detail preclinical data on Protagonist drug candidates PTG-100 ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, ... focused on venture growth investments in biotechnology and ... Josh Richardson , M.D. to Managing Director. ... companies.  He is a board observer at InfaCare ... Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor Therapeutics, ... clinical-stage biotechnology company developing first-in-class biological therapies for ... it has elected to terminate its license agreement ... receptor agonists, including Cenderitide. "Our decision ... as we prioritize our efforts to advance our ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/19/2017)... and PUNE, India , January 19, 2017 ... Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," the global biometric ... CAGR of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... security for both public and private sectors. Continue ... ...
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
Breaking Biology News(10 mins):